Biotechnology company and drug delivery platform
innovator Lexaria Bioscience (CSE: LXX) (OTCQX: LXRP) this
morning announced that it has identified improved performance features of a new
version of the DehydraTECH(TM) delivery platform primarily suitable for use in
solid oral dosage forms like capsules, tablets and pills for the
pharmaceutical, medical, and supplement markets. The company’s groundbreaking
use of a naturally sourced formulation enhancement more than doubles
DehydraTECH’s absorption performance compared to prior results. During the
company’s animal study, Lexaria tested its DehydraTECH delivery technology with
compounds postulated to behave in a synergistic fashion for enhancement of
gastro-intestinal absorption, which resulted in significantly enhanced
DehydraTECH performance. This new, enhanced DehydraTECH formulation delivers 8X
more CBD into blood and over 19X more CBD into brain tissue than standard
industry formulations. In addition, Lexaria has filed new patent applications
related to the recent innovations. The specific nature of the enhanced DehydraTECH
will remain undisclosed until the new patent filings are published for
proprietary reasons.
To view the full press release, visit http://ibn.fm/38QF0
About Lexaria Bioscience Corp.
Lexaria Bioscience has developed and out-licenses its
disruptive delivery technology, which promotes healthier ingestion methods,
lower overall dosing and higher effectiveness of lipophilic active molecules.
Lexaria has multiple patents pending in over 40 countries around the world and
has patents granted in the United States and Australia for utilization of its
DehydraTECH delivery technology. Lexaria’s technology provides increases in
intestinal absorption rates, more rapid delivery to the bloodstream, and
important taste-masking benefits for orally administered bioactive molecules
including cannabinoids, vitamins, nonsteroidal anti-inflammatory drugs
(NSAIDs), nicotine and other molecules. For more information, visit the
company’s website at www.LexariaBioscience.com.
NOTE TO INVESTORS: The latest news and updates
relating to LXRP are available in the company’s newsroom at http://ibn.fm/LXRP
About MissionIRNewsBreaks
MissionIRNewsBreaks provide
a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by
our Team of professional journalists that keep a constant eye on the markets,
these posts are designed to inform you on the latest happenings of our clients
and other publicly traded companies on our radar. From earnings, acquisitions
and agreements to conference attendance and clinical study results, our news
breaks keep you up-to-date with the day’s top movers. MissionIR is primarily
focused on strategic communications. We have executed countless communications
programs to address the needs of companies ranging from start-ups to
established industry leaders, gaining valuable experience and the expertise
necessary to determine the most effective strategy for any given situation.
Please see full terms of use and disclaimers on the Mission
Investor Relations website applicable to all content provided by MIR, wherever
published or re-published: http://www.missionir.com/disclaimer.html
